Dispensing pharmacy chains and direct anticoagulants: Potential associations with patient outcomes
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5749 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Steven Kozlowski und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Stroke, Atrial Fibrillation, Ischemic Stroke. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Food and Drug Administration, Centers for Medicare & Medicaid Services, CDER, FDA Intramural Safety Research Interest Group.
Abstract (Originalsprache)
Purpose
Pharmacy chains can differ with respect to the characteristics of their patient populations as well as their nonprescription products, services, and practices, and thus may serve as a surrogate for potential unmeasured confounding in observational studies of prescription drugs. This study evaluates whether a single‐source drug can have different patient outcomes based on the dispensing pharmacy chain.
Methods
Separate analyses for two anticoagulant drugs, rivaroxaban and apixaban, were conducted using Medicare Fee‐for‐Service claims evaluating the association between dispensing pharmacy chain and outcomes of acute myocardial infarction, ischemic stroke, intracranial hemorrhage, gastrointestinal (GI) bleeding, all‐cause mortality, and major GI bleeding. Inverse probability of treatment weighting (IPTW) was used to balance baseline covariates across pharmacy chain cohorts, and outcome association was assessed with a Cox Proportional Hazards model.
Results
We observed no differences in outcomes across pharmacy chains for apixaban recipients. Rivaroxaban recipients from pharmacy chain C, however, had lower rates of GI bleeding (adjusted HR 0.83; 95% CI 0.69–1.00) and ischemic stroke (adjusted HR 0.57; 95% CI 0.38–0.87) as compared to chain A in primary analyses with a 3‐day grace period. The results moved closer to the null when 14‐ and 30‐day grace periods were implemented.
Conclusions
These results suggest that dispensing pharmacy chains may have the potential to act as a confounder of associations between drug exposure and outcome in some observational studies. Additional studies of potential confounding by pharmacy chain are needed. Further evaluation of potential pharmacy chain effects on safe use would be of value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
- Acumen, LLC, Burlingame, California, USA.
- Centers for Medicare & Medicaid Services, Washington, DC, USA.
ORCID-Profile: Steven Kozlowski
Förderung
- U.S. Food and Drug Administration
- Centers for Medicare & Medicaid Services
- CDER, FDA Intramural Safety Research Interest Group
- Centers for Medicare and Medicaid Services
- Center for Drug Evaluation and Research
Zitieren
APA
Kozlowski, S., Tworkoski, E., Dharmarajan, S., Flowers, N., Kwist, A., Shangguan, S., Chillarige, Y., Wernecke, M., MaCurdy, T., Kelman, J. A., & Graham, D. J. (2024). Dispensing pharmacy chains and direct anticoagulants: Potential associations with patient outcomes. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5749
Vancouver
Kozlowski S, Tworkoski E, Dharmarajan S, Flowers N, Kwist A, Shangguan S, et al. Dispensing pharmacy chains and direct anticoagulants: Potential associations with patient outcomes. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5749
BibTeX
@article{Kozlowski2024,
author = {Kozlowski, Steven and Tworkoski, Ellen and Dharmarajan, Sai and Flowers, Natasha and Kwist, Andrew and Shangguan, Shanlai and Chillarige, Yoganand and Wernecke, Michael and MaCurdy, Tom and Kelman, Jeffrey A and Graham, David J},
title = {Dispensing pharmacy chains and direct anticoagulants: Potential associations with patient outcomes},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5749}
}
EUVIMED